Table 3.
Best tumor responses for study 206 (HER2− MBC) and 208 (HER2+ MBC)
| Study 206 (HER2− MBC; Eribulin Only) | Study 208 (HER2+ MBC; Eribulin + Trastuzumab) | |||||||
|---|---|---|---|---|---|---|---|---|
| With prior anthracycline (n = 27) | With prior taxane (n = 26) | With prior anthracycline and taxane (n = 20) | Without prior anthracycline or taxane (n = 23) | With prior anthracycline (n = 11) | With prior taxane (n = 23) | With prior anthracycline and taxane (n = 9) | Without prior anthracycline or taxane (n = 27) | |
| ORR, n (%) | 7 (25.9) | 7 (26.9) | 5 (25.0) | 7 (30.4) | 7 (63.6) | 13 (56.5) | 5 (55.6) | 22 (81.5) |
| 95 % CI | (11.1, 46.3) | (11.6, 47.8) | (8.7, 49.1) | (13.2, 52.9) | (30.8, 89.1) | (34.5, 76.8) | (21.2, 86.3) | (61.9, 93.7) |
| CR, n (%) | 0 | 0 | 0 | 0 | 2 (18.2) | 2 (8.7) | 1 (11.1) | 0 |
| PR, n (%) | 7 (25.9) | 7 (26.9) | 5 (25.0) | 7 (30.4) | 5 (45.5) | 11 (47.8) | 4 (44.4) | 22 (81.5) |
| PFS, median, m | 5.8 | 5.8 | 6.7 | 7.6 | 6.7 | 6.8 | 5.9 | 13.1 |
| 95 % CI | (2.5, 8.3) | (1.6, 7.3) | (2.5, 11.9) | (4.6, 12.4) | (1.4, NE) | (6.0, 13.5) | (1.4, NE) | (9.1, NE) |
m months, NE not estimable